BioInformant

Your Global Leader in Stem Cell Market Research

Direct Cell Reprogramming: What Is It and How Does It Work?

By 6 Comments

There has been tremendous activity over the last decade in the development of stem cells therapeutics, which have relied on stem cell differentiation protocols, as well as techniques for direct cell reprogramming. Today, there are over 5,400 stem cell trials registered on ClinicalTrials.gov and publications have increased dramatically in recent years, demonstrating the rapidly growing interest of the scientific community.

However, for all its promise, stem cells are yet to deliver on this therapeutic potential, and this failure appears due to various technical challenges that still need to be overcome. [Read more…]

Matica Biotechnology, Inc. Announces Groundbreaking for New GMP Facility

By Leave a Comment

Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in clinical and commercial production of cell and gene therapies, has broken ground on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located at Providence Park in College Station, Texas. [Read more…]

The New CO.DON Plant for the EU-approved Advanced Therapy Cartilage Regeneration Treatment Sets a Milestone in Cell Therapy for Commercial Manufacturing

By Leave a Comment

Human cell experts from Germany’s  CO.DON AG are again cutting the edge: they have launched human cells production on an industrial scale. The demanding quality standards required of the manufacturing conditions for human cell transplants led to the development of Integrated Isolator Technology (IIT) alongside industrial partners, which went into operation at CO.DON´s Teltow site in 1999. [Read more…]

AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy

By Leave a Comment

SEATTLE, March 2, 2021 — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities. [Read more…]

Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential

By Leave a Comment

March 23, 2021, Miami — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into a Material Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention (“CDC”) to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection. [Read more…]

BioInformant's World-Class Clients